HC Wainwright Lifts Earnings Estimates for Roivant Sciences

Roivant Sciences Ltd. (NASDAQ:ROIV) – Investment analysts at HC Wainwright lifted their Q3 2027 earnings per share (EPS) estimates for Roivant Sciences in a research note issued on Wednesday, March 4th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $0.32 for the quarter, up from their prior forecast of ($0.45). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Roivant Sciences’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Roivant Sciences’ Q4 2027 earnings at ($0.47) EPS and FY2027 earnings at ($1.03) EPS.

ROIV has been the topic of several other reports. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday. The Goldman Sachs Group upped their target price on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Leerink Partners raised their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Citigroup increased their target price on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $28.81.

Roivant Sciences Trading Down 3.2%

Shares of ROIV opened at $28.78 on Friday. The company’s fifty day simple moving average is $24.56 and its 200-day simple moving average is $20.03. The company has a market cap of $20.60 billion, a P/E ratio of -24.60 and a beta of 1.17. Roivant Sciences has a twelve month low of $8.73 and a twelve month high of $30.03.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Group AG raised its holdings in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares in the last quarter. Morgan Stanley increased its holdings in Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. increased its holdings in Roivant Sciences by 365.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after buying an additional 8,621,567 shares during the period. Assenagon Asset Management S.A. raised its stake in Roivant Sciences by 11,507.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after buying an additional 6,877,348 shares in the last quarter. Finally, Norges Bank purchased a new stake in Roivant Sciences during the fourth quarter worth $112,750,000. 64.76% of the stock is currently owned by institutional investors.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Daniel Allen Gold sold 375,784 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.50, for a total value of $9,958,276.00. Following the completion of the sale, the director directly owned 15,127,329 shares in the company, valued at approximately $400,874,218.50. This represents a 2.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mayukh Sukhatme sold 339,441 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $26.47, for a total value of $8,985,003.27. Following the transaction, the insider directly owned 19,148,664 shares in the company, valued at $506,865,136.08. The trade was a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,318,014 shares of company stock worth $315,727,023 over the last three months. Company insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.